Strategic Partnerships Alida has multiple active collaborations with Storm Therapeutics for RNA modification targeted cancer therapies and with Baylor College of Medicine's GARP Core, plus a DNAnexus data collaboration. These partnerships indicate strong channels for co-development and outsourced analytics, offering opportunities to expand with additional analytical services, end-to-end pipelines, and scalable sequencing workflows for pharma and academic customers.

RNA Modification Upsell The launch of the EpiPlex Duo-Mod Service enabling concurrent m6A and inosine mapping with integrated RNA expression profiling demonstrates an opportunity to upsell end-to-end RNA modification analysis, biomarker discovery, and diagnostic assay development integrated with expression data.

Pharma Academic Target Alida’s focus on cancer RNA modification, ongoing precision medicine outreach, and collaborations with academic and industry partners, complement funded research activity, creating a strong basis to pursue target discovery, biomarker programs, and companion diagnostics with pharma and biotech collaborators.

Cloud Data Platform DNAnexus collaboration and a modern data stack suggest readiness to offer cloud-based workflows, data management, and reproducible analytics services to CROs and biotech labs, enabling scalable data solutions and easier integration with client pipelines.

Funding Readiness With external funding from NHGRI SBIR grants and investor support, Alida is positioned to pursue funded collaborations, accelerate commercialization of RNA modification tools, and scale partnerships with pharma and academic customers.